Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating oral difelikefalin as an adjunct to topical corticosteroid for moderate to severe pruritus in atopic dermatitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Pruritus

Drugs mentioned

• Difelikefalin (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Pruritus, Atopic Dermatitis | Phase 3 | Status: TERMINATED